Header Logo

Connection

Lerato Mohapi to RNA

Back to Details
This is a "connection" page, showing publications Lerato Mohapi has written about RNA.
Lerato Mohapi
Connection Strength
0,050
RNA
  1. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
    View in: PubMed
    Score: 0,050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.